

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

A. For Equity Issues

Sr No	Name of the issue:	Astonea Labs Limited
--------------	---------------------------	-----------------------------

1	Type of issue (IPO/ FPO)	Initial Public Offering (IPO) on SME Platform of BSE
	Source: Prospectus of the Company	

2	Issue size (Rs. Lakhs)	3766.50
	Source: Prospectus of the Company	

3	Grade of issue alongwith name of the rating agency	Not Applicable
	Source: Prospectus of the Company	

4	Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.		
	Source: Final post-issue report dated	JUNE 04, 2025	1.43

5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Regulation 31 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015		
	Particulars	%	
	(i) allotment in the issue	12.56	
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (as on half year ended September 2025)	2.86	
	(iii) at the end of 1st FY (as on year ended March 2026)	0.07	
	(iv) at the end of 2nd FY (as on year ended March 2027)	NA	
	(v) at the end of 3rd FY (as on year ended March 2028)	NA	

Note:
 (1) Source: Basis of Allotment and Shareholding pattern as available on BSE
 (2) Total Outstanding Capital (no. of shares) is 1,05,11,000

6	Financials of the issuer (as per the annual financial results submitted to stock exchanges under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015			
		Amount in Lakhs		
	Parameters	1st FY (For the period ended March 31, 2026)	2nd FY (For the period ended March 31, 2027)*	3rd FY (For the period ended March 31, 2028)*
	Income from operations	8129.3	Not Available	Not Available
	Net Profit for the period	309.77	Not Available	Not Available
	Paid-up equity share capital	1051.10	Not Available	Not Available
	Reserves excluding revaluation reserves	4662.05	Not Available	Not Available

Source: BSE Filing of Financial Result
 Note: There is no bifurcation of Revaluation reserves is disclosed hence it is assumed that the Reserves is excluding Revaluation Reserves

7	Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of the SAST Regulations, 2011 or infrequently traded/ delisted/ suspended by any stock exchange, etc.)	
	Particulars	Status
	(i) at the end of 1st FY(March 31, 2026)	Active
	(ii) at the end of 2nd FY(March 31 2027)*	NA*
	(iii) at the end of 3rd FY(March 31 2028)*	NA*

*Trading status not disclosed as the relevant fiscal year has not been completed
 Source: BSE

8	Change, if any, in directors of issuer from the disclosures in the offer document (See Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015)		
	Particulars	Name of the Director	Appointed / Resigned
		Mr. Pardeep Singh	Retired by rotation at AGM held on 27.12.2025
	(i) at the end of 1st FY (March 31, 2026)	Mr. Vikrant	Appointed as Director w.e.f 10.11.2025

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

	Mr. Pardeep Dalal	Appointed as Director w.e.f 10.11.2025
	Mr. Arun Kumar Tripathi	Appointed as Director w.e.f 10.11.2025
(ii) at the end of 2nd FY (March 31, 2027)	NA	NA
(iii) at the end of 3rd FY (March 31, 2027)	NA	NA

Source: MCA and BSE

9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015)

(i) Details of Estimated Schedule of Implementation of Projects forming part of the Objects of the Issue as per Prospectus	NA
(ii) Actual implementation	NA
(iii) Reasons for delay in implementation, if any	NA

10 Status of utilization of issue proceeds (as submitted to stock exchanges under Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

(₹in Lakhs)

Object	As disclosed in Offer Document	*Revised Allocation (Post IPO)	Actual Utilisation as on 31.03.2026	Total Unutilised Amount as on 31.03.2026
Funding of expenses proposed to be incurred towards registration in Bolivia, South America	128.97	75.00	8.34	66.66
Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the 2nd floor of the Existing Premises	523.40	300.58	300.58	-
Advertising, marketing and brand building	495.15	200.15	200.15	-
Investment in procuring hardware and software	68.38	15.45	15.45	-
Funding of working capital requirements	1975.00	1975.00	1975.00	-
General corporate purposes	198.81	198.53	89.85	108.68
Issue Expense	376.79	376.79	376.79	-
*Investment in Equity Stake of Damaira Pharmaceuticals Private Limited	-	625.00	625.00	-
Total	3766.50	3766.50	3591.16	175.34

Source: BSE

Reasons for deviation, if any: *The Board of Directors of the Company, after due consideration and deliberation, in board meeting dated 27.02.2026 has approved a variation in the utilisation of the proceeds raised through the Initial Public Offering (IPO), with respect to the objects as disclosed and approved in the Prospectus. Subsequently, the said proposed variation in the utilisation of IPO proceeds was placed before the shareholders for their approval and was duly approved at the Extra-Ordinary General Meeting (EGM) of the Company held on 27.03.2026, in accordance with applicable statutory and regulatory requirements. Pursuant to the requisite approvals obtained from both the Board of Directors and the shareholders of the Company, the revised object of utilisation has been duly implemented. Accordingly, the entire amount pertaining to the approved deviation has been fully utilised towards the acquisition of an equity stake in Damaira Pharmaceuticals Private Limited on 30.03.2026, in line with the approved revised object of utilisation of IPO proceeds.

11 Comments of monitoring agency, if applicable (See Regulation 262 of ICDR Regulations, 2018 read with Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

i. Comments on use of funds	Not Applicable, since Issue size is less than Rs. 100 crores
ii. Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Not Applicable
iii. Any other reservations expressed by the monitoring agency about the end use of funds	Not Applicable

(To be submitted till the time the issue proceeds have been fully utilized)

12 Price- related data

Issue price (Rs):

Price parameters	At close of listing day (03-06-2025)	At close of 30th calendar day from listing day (02-07-2025)	At close of 90th calendar day from listing day (31-08-2025)	As at the end of 1st FY after the listing of the issue (31-03-2026)			As at the end of 2nd FY after the listing of the issue			As at the end of 3rd FY after the listing of the issue		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (BSE) -	135.65	145.85	174.70	159.60	185.00	118.00	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Index (of the Designated Stock Exchange): BSE Sensex	80,737.51	83,409.69	80,364.49	73,134.32	86,159.02	71,425.01	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Sectoral Index (mention the index that has been considered and reasons for considering the same)	NA	NA	NA	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
--	----	----	----	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------	---------------

Source: BSE

Note: In case any of the above reporting dates happens to be a holiday, the immediately following working day may be taken

- 13 **Basis for Issue Price and Comparison with Peer Group & Industry Average** (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	As disclosed in the offer document (See (9)(K) Schedule VI of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018) (as on March 2024)	At the end of 1st FY (31-03-2026)	At the end of 2nd FY	At the end of 3rd FY
EPS	Issuer: Astonea Labs Limited	5.01	4.49	Not Available	Not Available
	Peer: Beta Drugs Limited	37.9	40.92	Not Available	Not Available
P/E	Issuer: Astonea Labs Limited	26.95	34.10	Not Available	Not Available
	Peer: Beta Drugs Limited	49	29.06	Not Available	Not Available
RoNW	Issuer: Astonea Labs Limited	31.83%	7.90%	Not Available	Not Available
	Peer: Beta Drugs Limited	23.19%	16.95%	Not Available	Not Available
NAV per share based on balance sheet	Issuer: Astonea Labs Limited	15.75	54.35	Not Available	Not Available
	Peer: Beta Drugs Limited	163.43	241.49	Not Available	Not Available

Source: BSE and NSE Announcement

- 14 **Any other material information** **NIL**

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Oneview Corporate Advisors Private Limited ("OCAPL") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") (the "Stock Exchange"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.